Table 1. Demographic, Clinical, and Biochemical Characteristics of the Study Participants at Baseline.

Parameters		Atorvastatin (20 mg) (n=44)	Rosuvastatin (10 mg) (n=45)	Pitavastatin (2 mg) (n=42)	p value
Male		20 (45.4)	13 (28.8)	14 (33.3)	0.24
Age, yr		58.8±9.7	58.7±12.0	57.9±9.4	0.91
Hypertension		15 (34.1)	17 (37.8)	11 (26.2)	0.50
Antidiabetic drugs		35 (79.5)	32 (71.1)	33 (75.6)
	Metformin	8 (22.9)	10 (31.3)	9 (27.3)	0.88
	Metformin combinations*	23 (65.7)	20 (62.5)	21 (63.6)	0.75
	Others†	4 (11.4)	2 (6.2)	3 (9.1)	0.68
FPG, mg/dL		134.0 (122.5–149.7)	134.0 (121.0–147.0)	139.0 (112.0–185.3)	0.59
HbA1c, %		6.0 (6.5–7.8)	6.1 (6.8–8.2)	7.5 (6.4–9.4)	0.12
Total cholesterol, mg/dL		255.9±42.2	256.6±47.8	259.1±39.8	0.99
LDL-C, mg/dL		173.8±35	174.5±39.4	176.1±33	0.98
HDL-C, mg/dL		47.2±10.2	48.9±9.1	49±8.7	0.60
Triglycerides, mg/dL		177.5±64.4	172.6±68.2	179.5±66.9	0.88

FPG, fasting plasma glucose; HbA1c, Hemoglobin A1c; LDL-C, low-density lipoprotein-cholesterol; HDL-C, high-density lipoprotein-cholesterol.

Data are presented as means±SD, medians (Q1–Q3), or n (%). P-values refers to comparisons among drugs.

^*Metformin+ GLP-1 RA or DPP4 or SGLT-2 inhibitors; ^†Insulin+ metformin or DPP4 inhibitors.